A Phase 3, Randomized, Double-blind Study Of Pf-05280586 Versus Rituximab For The First-line Treatment Of Patients With Cd20-positive, Low Tumor Burden, Follicular Lymphoma
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Apr 2018
At a glance
- Drugs Rituximab (Primary)
- Indications Follicular lymphoma
- Focus Registrational; Therapeutic Use
- Acronyms REFLECTIONS
- Sponsors Pfizer
- 26 Jan 2018 Status changed from recruiting to active, no longer recruiting.
- 24 Jan 2018 According to a Pfizer media release, results of the study will be presented at a future medical meeting or summarized in publication.
- 24 Jan 2018 Primary endpoint has been met. (Objective Response Rate (ORR) according to the revised response criteria for malignant lymphoma), according to a Pfizer media release.